Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Pediatric Dosing of Ceftriaxone

Age-Specific Dosing Recommendations

  • The American Academy of Pediatrics recommends that for neonates with postnatal age ≤7 days, the dose of ceftriaxone is 50 mg/kg/day given every 24 hours 1
  • For neonates with postnatal age >7 days and ≤2000 g, the dose of ceftriaxone is 50 mg/kg/day given every 24 hours 1
  • For neonates with postnatal age >7 days and >2000 g, the dose of ceftriaxone is 50-75 mg/kg/day given every 24 hours 1
  • Ceftriaxone should not be used in hyperbilirubinemic neonates 1

Indication-Specific Dosing

  • For bacterial meningitis, the dose of ceftriaxone is 100 mg/kg/day divided every 12-24 hours (maximum 4 g daily) 2, 3, 4
  • For severe infections including pneumonia, the dose of ceftriaxone is 50-100 mg/kg/day given once daily or divided every 12-24 hours 5, 6
  • For less severe infections, the dose of ceftriaxone is 50-75 mg/kg/day given once daily or divided every 12-24 hours 2, 3
  • For community-acquired pneumonia, the dose of ceftriaxone is 50-100 mg/kg/day given once daily or divided every 12-24 hours 2, 3, 4
  • For pneumococcal pneumonia with penicillin resistance, the dose of ceftriaxone is 100 mg/kg/day given every 12-24 hours 4, 5
  • For complicated intra-abdominal infections, the dose of ceftriaxone is 50-75 mg/kg/day given every 12-24 hours 7
  • For sepsis, the dose of ceftriaxone is 50-75 mg/kg/day given every 12-24 hours 8

Ceftriaxone Dosing Guidelines

Pathogen-Specific Considerations

  • For gram-negative enteric bacilli, the American Academy of Pediatrics recommends a dose of 100 mg/kg/day divided every 12 hours or 80 mg/kg/day every 24 hours (up to 4 g daily) 9

Ceftriaxone Dosing Guidelines for Pediatric Patients

Special Considerations for Infections

  • For specific infections like gonococcal conjunctivitis in children weighing ≤45 kg, the dose is 25-50 mg/kg body weight intravenous or IM, single dose, not to exceed 250 mg IM 10

Ceftriaxone Dosing Guidelines for Pediatric Patients

Dosing Recommendations

  • For bacteremia or arthritis in pediatric patients, the American Academy of Pediatrics recommends a dose of 50 mg/kg/day (500 mg for a 10kg child) given daily for 7 days, with a strength of evidence based on MMWR Recommendations and Reports 11

Ceftriaxone Dosing in Pediatric Patients

Indication-Specific Dosing

  • For gram-negative enteric bacilli and streptococcal infections, the American Heart Association recommends a dose of 100 mg/kg/day divided every 12 hours or 80 mg/kg/day every 24 hours (up to 4 g daily) 12
  • For treatment of infective endocarditis caused by streptococci, the American Heart Association recommends ceftriaxone as 100 mg/kg/day divided every 12 hours or 80 mg/kg/day every 24 hours (up to 4 g daily) 12, 13

Ceftriaxone Pediatric Dosing Guidelines

Pathogen-Specific Dosing Considerations

  • The American Heart Association recommends 100 mg/kg/day IV/IM once daily for 4 weeks (native valve) or 6 weeks (prosthetic valve) for HACEK organisms (Endocarditis) 14

Administration Considerations

  • The American Heart Association suggests that IM injection of ceftriaxone is painful and patients should be counseled accordingly 14

Maximum Dose Limitations

  • The American Heart Association states that pediatric doses of ceftriaxone should not exceed adult doses (maximum 4 g daily) 14

Ceftriaxone Dosing Guidelines for Pediatric Patients

Standard Dosing by Infection Severity

  • The Centers for Disease Control and Prevention recommends 50 mg/kg/day (365 mg for a 7.3kg patient) given daily for 7 days for bacteremia or arthritis 15, 16, 17
  • For gonococcal infections in patients less than 45kg, the Centers for Disease Control and Prevention recommends an uncomplicated infection dose of 125 mg IM single dose 15, 16, 17
  • For gonococcal infections in patients less than 45kg with bacteremia or arthritis, the Centers for Disease Control and Prevention recommends 50 mg/kg/day for 7 days 15, 16, 17

Ceftriaxone Dosing for Severe Sepsis in Pediatric Patients

Pediatric Dosing Algorithm for Severe Sepsis

  • The British Journal of Pharmacology recommends standard dosing for severe infections in children is 50-100 mg/kg/day 18
  • The World Health Organization recommends 50 mg/kg twice daily (every 12 hours) for older child sepsis 18
  • The higher dosing range (80-100 mg/kg/day) is appropriate for severe sepsis, according to the British Journal of Pharmacology 18

Critical Considerations for Severe Sepsis

  • If staphylococcal infection is suspected, add flucloxacillin 50 mg/kg every 6 hours plus gentamicin 7.5 mg/kg daily, as recommended by the British Journal of Pharmacology 18
  • If Listeria is a concern, add ampicillin 50 mg/kg every 6 hours, according to the British Journal of Pharmacology 18

Common Pitfalls to Avoid

  • Do not use the lower end of the dosing range (50 mg/kg/day) for severe sepsis, as recommended by the British Journal of Pharmacology 18

Ceftriaxone Pediatric Dosing Guidelines

Indication-Specific Dosing

  • The Centers for Disease Control and Prevention recommends a single dose of 125 mg IM for uncomplicated infections, such as urethritis, cervicitis, pharyngitis, and proctitis 19
  • For bacteremia or arthritis, the CDC recommends 50 mg/kg IM or IV once daily for 7 days (maximum 1 g) 19
  • For meningitis, the CDC recommends 50 mg/kg IM or IV once daily for 10-14 days (maximum 2 g) 19
  • For children ≥45 kg, the CDC recommends using adult dosing regimens 19
  • For uncomplicated gonococcal infections, the CDC recommends a single dose of 125 mg IM 19
  • For gonococcal bacteremia, arthritis, or meningitis, the CDC recommends 50 mg/kg/day (maximum 1 g) for 7 days, and extend to 10-14 days for meningitis 19

Ceftriaxone Dosing Guidelines for Pediatric Patients

Standard Dosing Algorithm

  • For severe infections, such as pneumonia, sepsis, or complicated infections, in pediatric patients, the Infectious Diseases Society of America recommends a dose of 50-100 mg/kg/day, given once daily or divided every 12-24 hours 20
  • For pediatric patients with Streptococcus pneumoniae infections that have penicillin resistance, a dose of 100 mg/kg/day, divided every 12-24 hours, is recommended for adequate CNS penetration and treatment of resistant strains 20
  • For community-acquired pneumonia in pediatric patients, a dose of 50-100 mg/kg/day is recommended, with the higher end of the range preferred for hospitalized children or when high-level penicillin resistance is documented 20

Administration Guidelines

  • For intramuscular administration of ceftriaxone in pediatric patients, the American Heart Association recommends injecting deep into large muscle mass, and counseling the family that IM injection can be painful 21

Practical Considerations

  • For pediatric patients with moderate severity community-acquired pneumonia, a dose of approximately 60 mg/kg/day, such as 700 mg IV once daily, is a practical ordering example 20
  • The Infectious Diseases Society of America recommends not underdosing severe infections, and always using 100 mg/kg/day for life-threatening infections, empyema, or documented resistant pneumococcus 20

Ceftriaxone Dosing Guidelines

Standard Dosing Recommendations

  • The American Academy of Pediatrics recommends ceftriaxone dosing at 50-75 mg/kg/day for most infections in infants and children beyond the neonatal period, given once daily or divided every 12-24 hours, with a maximum daily dose of 2 grams for non-meningeal infections and 4 grams for meningitis 22
  • For neonates, the dosing recommendation is 50 mg/kg/day given every 24 hours, with a critical contraindication in hyperbilirubinemic neonates due to risk of bilirubin encephalopathy 22

Special Population Considerations

  • The Infectious Diseases Society of America recommends that ceftriaxone should not be used in hyperbilirubinemic neonates due to risk of bilirubin encephalopathy 22
  • For bacterial meningitis, the maintenance dose is 100 mg/kg/day divided every 12-24 hours, with a maximum of 4 grams daily 22

Ceftriaxone Dosing for Pediatric Pyelonephritis

Standard Pediatric Dosing Algorithm

  • The American Academy of Pediatrics recommends a standard dose of 50-75 mg/kg/day of ceftriaxone for infants and children beyond the neonatal period with pyelonephritis, given once daily or divided every 12-24 hours 23
  • For a patient weighing 18.9 kg with pyelonephritis, the appropriate dose is approximately 950-1,420 mg/day, given once daily or divided every 12-24 hours 23

Practical Dosing Recommendation

  • The Infectious Diseases Society of America recommends a dose of 1,000 mg (approximately 53 mg/kg) IV/IM once daily for a patient with pyelonephritis 23
  • An alternative dosing regimen is 500 mg IV every 12 hours, for a total of 1,000 mg/day 23

Guideline Recommendations for Antibiotic Management of Pediatric Community‑Acquired Pneumonia

First‑Line Empiric Therapy

  • The Infectious Diseases Society of America and Pediatric Infectious Diseases Society (IDSA/PIDS) recommend ceftriaxone or cefotaxime as the first‑line agents for hospitalized children with community‑acquired pneumonia. 24, 25, 26
  • In fully immunized children (vaccinated against Haemophilus influenzae type b and Streptococcus pneumoniae), ampicillin or penicillin G are preferred, with ceftriaxone or cefotaxime as acceptable alternatives. 24, 25

Spectrum of Ceftriaxone

  • Ceftriaxone provides excellent coverage of the principal bacterial pathogens in pediatric pneumonia, including Streptococcus pneumoniae (including penicillin‑resistant strains), Haemophilus influenzae (including β‑lactamase‑producing strains), and other gram‑negative organisms. 24, 25

Indications for Adding Clindamycin (or Vancomycin)

  • Clindamycin or vancomycin should be added only when community‑associated methicillin‑resistant Staphylococcus aureus (CA‑MRSA) is specifically suspected; routine use for consolidation is not recommended. 24, 25, 26
  • The IDSA/PIDS guidelines list specific clinical scenarios that trigger consideration of clindamycin (or vancomycin), such as necrotizing pneumonia, large pleural effusions, empyema, severe sepsis, rapid disease progression, recent influenza‑like illness, known MRSA colonization, failure to improve after 48–72 h of standard β‑lactam therapy, or high local CA‑MRSA prevalence. 24, 25, 26

Dosing Considerations for Severely Malnourished Children

  • Optimizing the current regimen is preferred; the guidelines emphasize using the higher end of the ceftriaxone dosing range (80–100 mg/kg/day) for severe pneumonia with consolidation in malnourished children. 24, 25

Clinical Monitoring and Decision Points

  • Reassessment at 48–72 h is advised: if the child shows clinical improvement (reduced fever, better respiratory status, improved feeding), continue the current ceftriaxone + gentamicin regimen. 24, 25
  • If there is no improvement or clinical deterioration at 48–72 h, consider:

Antibiotic Stewardship Principles

  • Empiric addition of antibiotics “just in case” is discouraged because it promotes resistance and increases toxicity without proven benefit. 24, 25
  • Consolidation on chest imaging alone does not justify anaerobic coverage; clindamycin’s primary role in pediatric pneumonia is for CA‑MRSA, not routine consolidation. 24, 25

Evidence Strength

  • The IDSA/PIDS 2011 guidelines constitute the highest‑quality evidence for pediatric pneumonia management and explicitly reserve clindamycin for cases with suspected CA‑MRSA rather than routine use. 24, 25, 26

Ceftriaxone Dosing Guidance for Adolescents Near the Adult‑Weight Threshold

Weight Conversion for Dosing Calculations

  • The CDC (MMWR Recommendations and Reports) specifies that a 15‑year‑old weighing 96 lb is equivalent to 43.6 kg, which is used for weight‑based dose calculations. 27

Indication‑Specific Pediatric Dosing

Uncomplicated Gonococcal Infection

  • For patients under 45 kg, the CDC recommends a single 125 mg intramuscular dose of ceftriaxone for uncomplicated gonococcal infection. 27

Weight Threshold Determining Adult vs. Pediatric Regimen

  • According to CDC guidelines, children weighing ≥45 kg should be treated with adult ceftriaxone dosing regimens, whereas those below this threshold receive pediatric dosing capped at the pediatric maximum (2 g daily for non‑meningeal infections). The patient at 43.6 kg therefore remains on the pediatric schedule. 27

Transition Considerations Near the 45 kg Cut‑off

  • The CDC notes that a patient weighing 96 lb (43.6 kg) is close to the 45 kg threshold, and for practical purposes a 2 g intramuscular dose once daily aligns with both the pediatric maximum and the lower end of adult dosing (1–2 g daily) for most infections. 27

Ceftriaxone Dosing Guidelines for Children

Uncomplicated Gonococcal Infection

  • For children weighing < 45 kg, a single intramuscular dose of 125 mg ceftriaxone is recommended; concomitant antichlamydial therapy (e.g., azithromycin) should be added when Chlamydia trachomatis has not been excluded. Evidence: guideline recommendation (Ophthalmology 2019). 28

Gonococcal Bacteremia, Arthritis, or Disseminated Infection

  • Ceftriaxone 50 mg/kg administered intramuscularly or intravenously once daily for 7 days (maximum 1 g per day) is advised for gonococcal bacteremia, arthritis, or disseminated infection. Evidence: CDC MMWR recommendations (moderate‑strength guideline). [29][30]
  • If meningitis is documented, the treatment duration should be extended to 10–14 days. Evidence: CDC MMWR recommendations (moderate‑strength guideline). [29][30]

General Pediatric Dosing Recommendations (Serious Infections & Meningitis)

  • The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) endorse the following pediatric ceftriaxone dosing:
    • Serious (non‑meningeal) infections: 50–75 mg/kg per day (once daily), not to exceed 2 g per day.
    • Bacterial meningitis: 100 mg/kg per day (either divided q12 h or once daily), with a maximum of 4 g per day.
  • These recommendations are based on FDA‑approved dosing and are supported by guideline consensus (strong recommendation). Evidence: CDC MMWR (1993) and AAP (Pediatrics 2021). [29][30]31

REFERENCES